Xencor, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bassil I. Dahiyat
- Full Time Employees
- 260
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 465 North Halstead Street Pasadena CA United States of America 91107
- IPO Date
- Dec 3, 2013
- CIK
- 0001326732
- Website
- xencor.com
- Similar Companies
- Business
- Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, specializing in the discovery and development of engineered monoclonal antibodies and protein therapeutics for the treatment of cancer, autoimmune diseases, asthma, allergic diseases, and infectious diseases. The company utilizes its proprietary XmAb® technology platform to create bispecific antibodies and Fc domain-engineered antibodies designed to improve efficacy, safety, and durability of therapeutic treatments. Key products and investigational candidates include XmAb bispecific antibodies targeting multiple disease mechanisms, XmAb Fc domain technologies for enhanced immune functions, and partnered products such as Tavneos for autoimmune vasculitis, Monjuvi for relapsed or refractory diffuse large B-cell lymphoma, Sotrovimab targeting SARS-CoV-2, and Plamotamab for certain cancers. Xencor also delivers contract research services through Vimta BioSciences. Recent major developments include an expanded collaboration with Caris Life Sciences to increase target discovery efforts using Caris’ multi-omics platform, supporting development of novel XmAb antibody drug candidates with milestone and royalty arrangements. In 2025, Xencor has advanced multiple clinical-stage programs: ongoing Phase 1 studies for XmAb819 in renal cell carcinoma and XmAb541 in cancer; a Phase 2b study for XmAb942 in ulcerative colitis; and progressing development of Plamotamab in rheumatoid arthritis. Financially, the company reported a 42% revenue increase to $618.8 million in 2024 and milestone payments from partners such as Incyte and Vir Biotechnology. Leadership transitions include the Chief Development Officer moving to a senior advisory role. Xencor maintains a strong cash position expected to fund operations well into 2028, reflecting strategic growth and sustained investment in its pipeline. The company was founded in 1997 and operates globally, leveraging strategic partnerships with pharmaceutical leaders like Amgen and Novartis to develop and commercialize its XmAb-based therapeutics. Xencor’s proprietary technology platforms, diverse pipeline of antibody therapies, and recent clinical and commercial advancements position it at the forefront of protein engineering-based biopharmaceutical innovation. Its focus includes expanding therapeutic applications across oncology, autoimmune, and inflammatory diseases with the aim to improve patient outcomes and quality of life. Overall, Xencor offers a comprehensive portfolio of engineered antibody therapeutics and research collaborations, backed by robust scientific expertise and a growing clinical pipeline targeting challenging diseases worldwide.
Company News
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor (NASDAQ:XNCR) Shares Up 4.6% – What’s Next?
Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE
Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR
Xencor to Present at the 2026 Cantor Global Healthcare Conference
Xencor (NASDAQ:XNCR) Sets New 52-Week High – Should You Buy?
Dimensional Fund Advisors LP Buys 45,599 Shares of Xencor, Inc. $XNCR
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
Xencor Reports Second Quarter 2026 Financial Results
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor: Bullish On Their Increasingly In-House Pipeline
The Biology Came First.
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor Reports First Quarter 2026 Financial Results
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW